Current diagnosis and treatment for myelodysplastc syndromes.

Abstract excerpt

Genetic analysis of myelodysplastic syndrome (MDS) using next-generation sequencing yields medcially important information, showing gene mutations in 90% of MDS cases. The World Health Organization (WHO) classification was revised in 2016 to incorporate SF3B1 gene mutations, frequently seen in MDS with ringed sideroblasts, into the diagnostic criteria. Unlike the poor prognosis seen in cases with ASXL1, EZH2,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Azacitidine
• Share to Drug Discovery
• Share to ASXL1 gene